Phase 2 Trial Shows Nilotinib Potential to Modulate Dopamine in Parkinson’s
Phase 2 Trial Shows Nilotinib Potential to Modulate Dopamine in Parkinson’s
Phase 2 Trial Shows Nilotinib Potential to Modulate Dopamine in Parkinson’s |
I can only find the Abstract describing this research:
https://www.iaprd-world-congress.com..._Abstracts.pdf The conclusions: "a single time oral administration of Nilotinib may increase brain dopamine levels and metabolism. These results suggest Nilotinib, in a dose dependent manner, may have a symptomatic effect through modulation of brain dopamine levels. Additionally, the significant reduction of oligomeric alpha-synuclein, which is expected to increase in the CSF of PD patients as the disease progresses, suggests that Nilotinib may reduce misfolded alpha-synuclein accumulation and have a longterm disease modifying effect. Importantly, the dose response of oligomeric alpha-synuclein and HVA changes to nilotinib suggests that the dose administered may depend on the stage of disease to potentially halt PD progression." John |
Quote:
|
Too soon
I think an "abstract" is all we are likely to get for quite a while yet. As it says in the PNT article, the Georgetown Phase 2 trial is still ongoing.
|
Quote:
https://www.fda.gov/forpatients/appr...st/default.htm |
From the conclusion:
"Importantly, the dose response of oligomeric alpha-synuclein and HVA changes to nilotinib suggests that the dose administered may depend on the stage of disease to potentially halt PD progression." I had a lot of trouble understanding this sentence, and I found the PNT article to be of no help in that regard. Assuming I've understood it correctly, here is an alternative wording that might (or might not!) be clearer: "The dose-dependent decrease in oligomeric alpha-synuclein levels (and increase in HVA/DOPAC levels) suggests that (to potentially halt PD progression) the stage-of-disease may dictate the appropriate dose of nilotinib to administer." Anyway, it seems to me that there is still a lot of research to be done to establish the correct dose for each stage of the disease. This might well affect the prospects for a fast-track approval. Hopefully, another write-up will appear (from AlzForum, SoPD blog, ...) and shed some more light. |
Quote:
June 17, 2018 - The competition to stop/reverse Parkinson's is intense! Our efforts to slow/halt the progression of Parkinson’s are attempting to attack the condition on many different fronts, and (as in the case of the cAbl-inhibitors and GLP-1 agonists – see previous post) we now have multiple weapons potentially available on some of those battle lines. Ironically in another recent post I commented about the crazy pace of the research at the moment (Click here for that post), and this post is a perfect example of that manic speed. Just days after publishing fascinating results dealing with a novel GLP-1 agonist in models of Parkinson’s, that same research group – led by Prof Han Seok Ko of Johns Hopkins University Medical school – published the research report that was reviewed in this post dealing with a completely different type of drug that exhibits interesting properties in models of Parkinson’s. A lot of excitement is associated with the efforts to re-purpose the cancer drug Nilotinib for Parkinson’s, and today’s post reinforces the idea that other pharmaceutical companies are also focusing on shifting similar ABL inhibitor drugs to neurodegenerative conditions. It will be interesting to see how quickly Ilyang Pharmaceutical initiates clinical testing of Radotinib for Parkinson’s. |
Quote:
Yes, as Jeff replied, this was only presented as an Abstract at the Oral Poster Presentation of the 2018 iaprd. This is a common occurrence to present abstracts and posters of ongoing clinical resesrch to provide updates as data is analysed. |
Quote:
|
Quote:
|
All times are GMT -5. The time now is 09:55 AM. |
Powered by vBulletin Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.